HighVista Strategies LLC Invests $257,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA)

HighVista Strategies LLC purchased a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,078 shares of the company’s stock, valued at approximately $257,000.

Several other large investors have also recently bought and sold shares of the stock. Oppenheimer & Co. Inc. acquired a new stake in shares of Tyra Biosciences in the 1st quarter valued at approximately $977,000. Vanguard Group Inc. grew its position in shares of Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after acquiring an additional 140,833 shares during the period. Kynam Capital Management LP acquired a new position in shares of Tyra Biosciences during the 4th quarter worth about $4,712,000. Wellington Management Group LLP increased its stake in shares of Tyra Biosciences by 8.8% during the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after purchasing an additional 8,324 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after purchasing an additional 14,352 shares during the period. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Stock Up 1.5 %

NASDAQ TYRA opened at $24.36 on Monday. Tyra Biosciences, Inc. has a 12-month low of $10.38 and a 12-month high of $25.14. The firm has a 50-day moving average price of $21.29 and a two-hundred day moving average price of $18.72. The company has a market capitalization of $1.28 billion, a P/E ratio of -14.50 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Equities analysts expect that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Oppenheimer lifted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday. Piper Sandler started coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.40.

Insider Buying and Selling at Tyra Biosciences

In related news, CEO Todd Harris sold 5,698 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total value of $138,518.38. Following the sale, the chief executive officer now owns 1,496,729 shares of the company’s stock, valued at $36,385,481.99. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 15.40% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.